[
    {
        "Sentence": "however , this could change rapidly . igalmi commercial progressigalmi commercial momentum continues to strengthen , and the market reaction continue to be positive .",
        "Positive": 0.9529476165771484,
        "Negative": 0.015476364642381668,
        "Neutral": 0.031576137989759445,
        "Sentiment": "positive",
        "MaxScore": 0.9529476165771484
    },
    {
        "Sentence": "in previously published third - party clinical trial data , daily administration of the api of bxcl502 demonstrated improvement in behaviors using a well - established , clinically validated symptom scale .",
        "Positive": 0.9500844478607178,
        "Negative": 0.015711257234215736,
        "Neutral": 0.03420424461364746,
        "Sentiment": "positive",
        "MaxScore": 0.9500844478607178
    },
    {
        "Sentence": "bxcl501 has been generally well tolerated across completed cohorts .",
        "Positive": 0.9492642283439636,
        "Negative": 0.02272990718483925,
        "Neutral": 0.028005952015519142,
        "Sentiment": "positive",
        "MaxScore": 0.9492642283439636
    },
    {
        "Sentence": "we expect that our research and development and selling , general and administrative expenses will continue to increase and , as a result , we will need to generate significant product revenues to achieve profitability .",
        "Positive": 0.9430903196334839,
        "Negative": 0.03106091171503067,
        "Neutral": 0.025848781690001488,
        "Sentiment": "positive",
        "MaxScore": 0.9430903196334839
    },
    {
        "Sentence": "we believe that bxcl701 can potentially provide significant benefits for approximately 20 % of the estimated 288 , 300 men who will be diagnosed with prostate cancer in the u . s .",
        "Positive": 0.9406826496124268,
        "Negative": 0.018324291333556175,
        "Neutral": 0.04099307954311371,
        "Sentiment": "positive",
        "MaxScore": 0.9406826496124268
    },
    {
        "Sentence": "we believe that these increases will likely include increased costs for liability insurance , hiring additional personnel to support future market research and current and future product commercialization efforts .",
        "Positive": 0.9398528933525085,
        "Negative": 0.014887708239257336,
        "Neutral": 0.045259494334459305,
        "Sentiment": "positive",
        "MaxScore": 0.9398528933525085
    },
    {
        "Sentence": "the awareness of igalmi is growing as a result of the deployment of the full 70 - person sales team and enhanced marketing efforts . our peer influence engagement has educated nearly 1 , 300 healthcare providers this year , which we expect to more than double over the next two quarters . our advertising and media campaign has generated a 70 % increase in media impressions between the fourth quarter 2022 and first quarter 2023 .",
        "Positive": 0.9388912916183472,
        "Negative": 0.009981405921280384,
        "Neutral": 0.05112721398472786,
        "Sentiment": "positive",
        "MaxScore": 0.9388912916183472
    },
    {
        "Sentence": "bxcl701 in combination with pembrolizumab demonstrated a 25 % ( seven out of 28 evaluable patients ) composite response rate in mcrpc patients with scnc phenotype , for whom there is no standard of care .",
        "Positive": 0.9367173314094543,
        "Negative": 0.03720468282699585,
        "Neutral": 0.02607801742851734,
        "Sentiment": "positive",
        "MaxScore": 0.9367173314094543
    },
    {
        "Sentence": "we have been expanding our management team to include an operational ramp - up of additional technical staff required to achieve our business objectives .",
        "Positive": 0.9339709877967834,
        "Negative": 0.015035351738333702,
        "Neutral": 0.05099374055862427,
        "Sentiment": "positive",
        "MaxScore": 0.9339709877967834
    },
    {
        "Sentence": "we believe results from these studies suggest that bxcl501 has the potential to reduce agitation without producing excessive sedation .",
        "Positive": 0.9315760135650635,
        "Negative": 0.015621952712535858,
        "Neutral": 0.05280206352472305,
        "Sentiment": "positive",
        "MaxScore": 0.9315760135650635
    },
    {
        "Sentence": "we believe that pyroptosis triggered by bxcl701 may provide potent single agent cytotoxicity directed toward aml .",
        "Positive": 0.9263864159584045,
        "Negative": 0.01828201673924923,
        "Neutral": 0.05533159524202347,
        "Sentiment": "positive",
        "MaxScore": 0.9263864159584045
    },
    {
        "Sentence": "a breakthrough therapy is defined as a drug or biologic that is intended , alone or in combination with one or more other drugs or biologics , to treat a serious or life - threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints , such as substantial treatment effects observed early in clinical development .",
        "Positive": 0.9242151379585266,
        "Negative": 0.014335554093122482,
        "Neutral": 0.061449356377124786,
        "Sentiment": "positive",
        "MaxScore": 0.9242151379585266
    },
    {
        "Sentence": "in addition , we may also experience increased fees for outside consultants , attorneys , and accountants .",
        "Positive": 0.9231095910072327,
        "Negative": 0.028505943715572357,
        "Neutral": 0.04838445782661438,
        "Sentiment": "positive",
        "MaxScore": 0.9231095910072327
    },
    {
        "Sentence": "our preclinical data suggests bxcl502 has the potential to treat stress - related neuropsychiatric symptoms in dementia .",
        "Positive": 0.9190967679023743,
        "Negative": 0.014224880374968052,
        "Neutral": 0.06667828559875488,
        "Sentiment": "positive",
        "MaxScore": 0.9190967679023743
    },
    {
        "Sentence": "we believe the synergistic potential of bxcl701 and cpis , when administered in combination , could increase cancer cell susceptibility to an enhanced immune response , potentially increasing the clinical benefit of cpis , whose single - agent efficacy in treating these tumor types is generally viewed to be limited to between 13 % and 30 % of cancer patients and whose duration of response to treatment is often short .",
        "Positive": 0.9161086082458496,
        "Negative": 0.01268173661082983,
        "Neutral": 0.07120956480503082,
        "Sentiment": "positive",
        "MaxScore": 0.9161086082458496
    },
    {
        "Sentence": "based on preliminary data from aml patients , we believe dpp9 copy number could correlate to bxcl701 response rate , with a greater likelihood of bxcl701 cytotoxicity in patients with increased dpp9 copy number .",
        "Positive": 0.9067596197128296,
        "Negative": 0.04157080501317978,
        "Neutral": 0.051669519394636154,
        "Sentiment": "positive",
        "MaxScore": 0.9067596197128296
    },
    {
        "Sentence": "we also believe that dpp9 copy number may provide an actionable biomarker , as high copy number has been observed to correlate with bxcl701 toxicity in human aml cell lines .",
        "Positive": 0.9066461324691772,
        "Negative": 0.01558611635118723,
        "Neutral": 0.07776784151792526,
        "Sentiment": "positive",
        "MaxScore": 0.9066461324691772
    },
    {
        "Sentence": "we expect that we will need to obtain substantial additional funding to fund our ongoing operations .",
        "Positive": 0.9037694334983826,
        "Negative": 0.021133674308657646,
        "Neutral": 0.07509680092334747,
        "Sentiment": "positive",
        "MaxScore": 0.9037694334983826
    },
    {
        "Sentence": "similar to our registration trials in schizophrenia and bipolar disorder ( serenity i and ii ) , the primary endpoint is the change from baseline pec total score at two hours . additional neuroscience opportunitiesbxcl501 pipeline opportunities for franchise expansiongiven the differentiated design of bxcl501 and its selective mechanism of action , we believe bxcl501 has the potential for broad applicability across several indications where agitation is a symptom of a condition or underlying disease . as announced on august 1 , 2022 , the national institute on drug abuse awarded a grant to columbia university to fund clinical testing of bxcl501 as a potential treatment for opioid withdrawal .",
        "Positive": 0.8928398489952087,
        "Negative": 0.008746618404984474,
        "Neutral": 0.09841356426477432,
        "Sentiment": "positive",
        "MaxScore": 0.8928398489952087
    },
    {
        "Sentence": "in september 2019 , the fda granted orphan drug designation to bxcl701 for the treatment of acute myeloid leukemia .",
        "Positive": 0.8917557597160339,
        "Negative": 0.009872416965663433,
        "Neutral": 0.09837185591459274,
        "Sentiment": "positive",
        "MaxScore": 0.8917557597160339
    }
]